Alexion Pharmaceuticals is a global biopharmaceutical company with more than 5,000 employees focused on developing and delivering transformative medicines for rare diseases. Its scientific work centres on translating the complex biology of the complement system into targeted therapies. The company operates across the rare diseases, pharmaceuticals, and biotechnology sectors, maintaining a worldwide presence.
Alexion's stated values include following the science, putting patients first, and thinking entrepreneurially. The firm describes its culture as patient-focused and collaborative, drawing on diverse perspectives and an entrepreneurial spirit. Its technical expertise is rooted in rare disease biology and the complement system.
Headquartered in the United States, Alexion became part of the AstraZeneca group in 2021. The company's operational scale and global reach support its mission to serve patients with rare conditions across multiple markets.
